The aim of the present study based on the PriCoTTF‐phase I/II trial is the quantification of skin‐normal tissue complication probabilities of patients with newly diagnosed glioblastoma multiforme treated with Tumor Treating Field (TTField) electrodes, concurrent radiotherapy, and temozolomide. Furthermore, the skin‐sparing effect by the clinically applied strategy of repetitive transducer array fixation around their center position shall be examined.

中文翻译：

---

PriCoTTF I / II期试验中肿瘤治疗场电极位置变化的剂量学影响

本研究基于PriCoTTF I / II期试验的目的是量化经肿瘤治疗场（TTField）电极，同时放疗和替莫唑胺治疗的新诊断成胶质母细胞瘤患者皮肤正常组织并发症的可能性。此外，应检查临床应用的重复换能器阵列围绕其中心位置固定的策略对皮肤的保护作用。